
eantargia

We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target

> Göran Forsberg, CEO September 2021

Safe Harbour Statement




Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forwardlooking statements will prove to be correct. Prospective investors should not place undue reliance on forwardlooking statements. They speak only as at the date of this Investor Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company undertakes no obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.





Cantargia – Opportunity to save lives and create value






Cantargia highlights

	 UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT First in class antibody with broader MOA than competitors Positive clinical interim data and further results during 2021
	 VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS Combination strategy based on synergies with established therapies
	 PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS Target IL1RAP found on most solid tumor forms and leukemia IL1RAP signalling (IL-1, IL-33 and IL-36) in large number of diseases
	 HIGHLY RELEVANT RESEARCH WITHIN CLINICALLY VALIDATED MECHANISMS Focus on opportunities with major unmet medical need
÷	 ROBUST PATENT PORTFOLIO Global patent families on IL1RAP as antibody target in oncology until 2032 and CAN04 until 2035
ม้ไ	 NASDAQ STOCKHOLM MAIN LIST ~12,000 SHAREHOLDERS AND LONG TERM INVESTORS Market cap: SEK 2.2bn (USD ~250m) (20 Sep-21) Cash: SEK 761m (USD 87m) (30 Jun-21)


Current owners (30 Jun 2021)

Swedbank Robur Funds	9.7%
4th AP fund	8.7%
Alecta	7.0%
1st AP fund	6.3%
Six Sis AG	5.7%
Avanza Pension	4.4%
SEB AB, Luxemburg	3.2%
Sunstone LSV	3.0%
Handelsbanken fonder	2.8%
Unionen	2.0%






II. LEAD ANTIBODY NADUNOLIMAB (CAN04)



CAN04 – Mechanism of action

7



CAN04 BLOCKS BOTH FORMS OF IL-1 AND CAN ERADICATE CELLS MEDIATING THE EFFECTS OF IL-1


Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated Fibroblast. NK = Natural Killer. MCP = Monocyte Chemoattractant Protein. MMP = Matrix Metallopeptidase. IL = Interleukin. VEGF = Vascular Endothelial Growth Factor



CAN04 – Differentiated and superior MOA

	Cancer cont	ext	IL-1α			IL-1β		comment
IL- <u>1α</u> IL- <u>1β</u>	Localization		und and sol cells and s		• So	luble	enhanc	rigger and IL-1β e inflammation vork in pair
ILLIRAD	Function	 Stimulates inflammation - IL1R1 -forming complex with IL1RAP IL-1, IL1R1 and IL1RAP in complex - essential for signal Note: Significant differences in amino acid sequence 						wn difference in nduced by the 2
	Clinical data fro blockade	• Signal • NSCLC	of benefit ir	n CRC and		ANTOS: reduce lung cancer cidence and death		
	Company	Compound	IL-1α	IL-1β	ADCC	Indication/dev phase		
TRAF6	Cantargia	CAN04	++	++	++	Pancreatic cancer, NSCLC ph	nase lla	
IKK TAK1 TAB2 MAPK	Xbiotech/ Janssen	Xilonix XB2001	++	-	+	 Autoimmunity, dermatology Pancreatic cancer, phase I 	/	
ІКВ РЗВ ЛМК	Novartis	Canakinumab Gevokizumab	-	++	-	 Autoimmunity, registered NSCLC, phase III Cancer comb, phase II 		
	Flame Biosci.	FL-101	-	++	-	NSCLC		
NFKB AP-1	Buzzard	Isunakinra	++	++	-	Cancer phase I		
	SOBI	Kineret	++	++	-	Autoimmunity, reg		
	Regeneron/ Kiniksa	Rilonacept	++	++	-	Autoimmunity, regPericarditis		
	R-Pharm	RPH-104	+	++	-	Pericarditis, inflammatory d	isease	eantargia

CAN04 broad mechanism uniquely enhance docetaxel antitumor activity




- → CAN04 in combination with docetaxel in MC38 syngeneic model
- → CAN04 increase efficacy of docetaxel
- $\rightarrow~$ Control antibody blocking IL-1 β did not have the same effect
- ightarrow In vitro experiment show docetaxel increase IL-1lpha production
- \rightarrow Highlight importance of blocking both forms of IL-1 to increase docetaxel efficacy

eantargia

→ Clinical trial investigating CAN04 + docetaxel being initiated.

DIFFERENTIATING FROM IL-1B BLOCKADE, CAN04 INCREASE DOCETAXEL EFFICACY

Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)



SYNERGY WITH CHEMOTHERAPY IN LINE WITH CURRENT DEVELOPMENT STRATEGY




Combination data in NSCLC show promising efficacy

	Total NSCLC (27 pts)	Historical control ^{1,2}	Non-squamous NSCLC (15 pts)	Historical control ³	Squamous NSCLC (11 pts)	Historical control⁴	PDAC (33 pts)	Historical control⁵	
ORR	48%	22-28%	53%	19%	36%	38%	27%*	23%	
PFS	7.2 mo	5.1 mo	NR**		NR**		7.8 mo	5.5 mo	
Ongoing treatment	11 pts (41%)		6 pts (40%)		5 pts (45%)		7 pts (21%)		

Summary of key interim results

*15% additional patients benefit with a pseudoprogression-like response **NR (not reported); will be analyzed with more mature data



- \rightarrow CAN04 in combination with gem/cis in 1st line chemotherapy
- → 13* of 27 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (48% vs historical control data 22-28%)
- → No major side effects observed except those from chemotherapy or CAN04 alone. Neutropenia frequency higher than expected from chemo (treated with dose reductions/GCSF)

*Incl 2 patients awaiting second conf scan


DEVELOPMENT ADVANCING IN SEVERAL SEGMENTS OF NSCLC

Schiller et al, N Engl J Med 2002; 346:92–98
 Scagliotti et al, J Clin Oncol 2008; 26:3543–3551
 Gandhi et al, N Engl J Med 2018; 378:2078-2092
 Paz-Ares et al, N Engl J Med 2018; 379:2040-2051



11 Note: CR Complete response, PR Partial response, SD Stable disease, PD progressive disease

Strong signal in non-squamous NSCLC



- \rightarrow CAN04 in combination with gem/cis in 1st line chemotherapy
- → 8 of 15 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (53% vs historical control data 19%)
- \rightarrow The complete response ongoing for >1.5 years
- $\rightarrow\,$ 8 patients were second line to pembrolizumab monotherapy, with 6 responses
- → No major side effects observed except those from chemotherapy or CAN04 alone. Neutropenia frequency higher than expected from chemo (treated with dose reductions/GCSF)




eantargia


DEVELOPMENT ADVANCING TOWARDS RANDOMIZED TRIAL END 2022

Positive data in pancreatic cancer

CAN04 in combination with gem/abraxane in 1st line :

- Durable responses observed (median DOR 6.8 mo, 27% response rate)
- Important finding of pseudoprogression-like response in 5 (15%) patients predicting long PFS.
- Promising PFS (7.8 mo) and OS (12.6 mo, 42 % events), seven patients still on treatment






eigentargia

EXTENSION PHASE TO OBTAIN MORE INFORMATION ON VARIOUS DOSE LEVELS ONGOING DURABLE RESPONSES AND PSEUDPROGRESSION LEADS TO LONG PFS

13

Patients with Pseudoprogression-like response



eantargia

PSEUDOPROGRESSION VERY UNCOMMON IN PANCREATIC CANCER INDICATE IMMUNE RELATED MECHANISM OF CAN04 LEADING TO LONG TERM BENEFIT

14

CAN04/GN in PDAC safety summary and benchmark

Grade 3 or higher AEs	Gem/Abraxane (von Hoff) N=421	CANFOUR CAN04/GN N=36	FOLFIRINOX (Conroy 2011) N=171
Neutropenia	38%	67%	46%
Febrile neutropenia	3%	17%	5%
Thrombocytopenia	13%	19%	9%
Anemia	13%	14%	8%
Fatigue	17%	6%	24%
Peripheral neuropathy	17%	0%	9%
Diarrhea	6%	3%	13%
Elevated ALT	ND	3%	7%
IRR	ND	3%	ND

The beneficial effect in fatigue and chemotherapyinduced neuropathy² (nabpaclitaxel or oxaliplatin) can be mediated by IL-1 blockade.


eipretne

- G-CSF not used proactively/prophylactically in this trial. In later trials, G-CSF counteracts neutropenia.
- Median duration of treatment 4.8 months (reference 3.9 months)


15

Most common reasons for termination: gastrointestinal events or general health deterioration

WITHOUT PROACTIVE USE OF G-CESF, NEUTROPENIA AND FEBRILE NEUTROPENIA HIGHER THAN CHEMOTHERAPY ALONE NEUROPATHY AND FATIGUE LOWER THAN EXPECTED FROM CHEMOTHERAPY




III. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES



CAN10 – New development project


- → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36
- → Unique anti-inflammatory activity observed in different mouse models (myocarditis, psoriasis, inflammation)
- → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on scientific rational, medical need, development opportunity and competition
- \rightarrow Clinical trials start early 2022



eantargia

UNIQUE OPPORTUNITY FOR CAN10 IDENTIFIED IN LIFE-THREATENING DISEASES


mCAN10 improves heart function in experimental autoimmune myocarditis




STRONG SUPPORT FOR SELECTION OF DEVELOPMENT STRATEGY

Oantargia

11



IV. MILESTONES AND SUMMARY



Cantargia reached several milestones and have several value inflection points in near future

Newsflow over next 6 months

Nadunolimab (CAN04)

- \rightarrow New results PDAC, NSCLC and Keytruda combination
- \rightarrow Randomized trials PDAC and NSCLC
- → New preclinical and translational results
- \rightarrow New clinical trials
 - CAPAFOUR FOLFIRINOX combination PDAC
 - CESTAFOUR Basket trial (NSCLC, CRC, BTC)
 - TRIFOUR TNBC

CAN10

- → Preclinical progress
- → Development milestones
- \rightarrow and initiation of clinical trial early 2022



eantargia

SIGNIFICANT DATA TO SECURE NEWSFLOW





